TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

O Hamid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.